Advanced Urothelial Cancer: Applying New Therapeutic Options, Part 1

PCE

Feb 11, 2022•31 min•Ep. 32

--:--

Listen in podcast apps:

Apple Podcasts

Spotify

Download

Listen to this episode in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Ms Sims: consulting fees: Coloplast.

For the best experience, listen in Metacast app for iOS or Android